SolasCure selected for Innovate UK Global Incubator Programme in Houston
Programme delivered in partnership with the Texas Medical Centre Programme will support Aurase Wound Gel for future entry into US market, advancing SolasC
SolasCure Awarded £405K Innovate UK Biomedical Catalyst Grant to Advance Chronic Wound Care
Funding will be used to further optimize Aurase Wound Gel for future clinical trials SolasCure aims to deliver the first effica
SolasCure announces completion of GBP 10.9m Series B investment round to advance wound care innovation
Funding will support the development of Aurase Wound Gel and progress toward further Phase II clinical trials of innovative wound debriding enzyme
Cambridge biotech company earns international recognition as first trial patient receives treatment
SolasCure, a Cambridge-based biotech company developing revolutionary wound-cleaning technology, sees its first trial patient receive treatment.
SolasCure begins clinical trials of its investigational wound cleaning product
Cambridge-based biologics company SolasCure has received authorisation to conduct clinical trials for its investigational product, Aurase Wound Gel, from the UK’s Medical and Healthcare products Regulatory Agency (MHRA) and approval to open its Investigational New Drug (IND) application by the FDA in the US.
SolasCure announces £15m Series A raise
Biotech start-up SolasCure has announced the completion of its Series A investment round, to support the development of its wound cleaning product, Aurase®. The Cambridge based biotech company has successfully completed its Series A raise of £15m, with funding from industry veterans, institutional ventures and strategic investors.